Aurobindo received Perampanel approval: USD 67 million matters for Aurobindo stock

Published on 10/25/2026 at 00:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Perampanel tablets won USFDA approval on October 3, 2026 for Aurobindo's specialty pipeline. Aurobindo stock has INR 91.5 billion Q1 revenue.

Perampanel approval and growth figures

Aurobindo had received Perampanel approval on October 3, 2026, with a USD 67 million market estimate.
Q1 2027 revenue reached INR 91.5 billion, while net income rose to INR 10.3 billion.
Aurobindo Pharma had a market capitalization of INR 904.3 billion as of October 23, 2026.

Aurobindo, INE406A01037, Illustration mit AI erstellt.

Aurobindo Pharma (INE406A01037) had received USFDA approval for Perampanel tablets on October 3, 2026, opening a product opportunity tied to a USD 67 million market. The approval gives Aurobindo stock a concrete specialty-pharma catalyst as the company broadens its portfolio beyond traditional generics, according to TradeAlone.

Three approvals build the pipeline

On September 15, 2026, Aurobindo had received approval for a beclomethasone inhalation aerosol linked to a USD 301 million US market. On September 30, 2026, its subsidiary Acrotech had launched ADQUEY ointment in US dermatology, targeting a USD 1.3 billion opportunity. On October 3, 2026, Perampanel approval covered six strengths and a planned launch in the third quarter of fiscal 2027, according to StockFin.

What does the latest quarter show?

Aurobindo reported Q1 2027 revenue of INR 91.5 billion, up from INR 78.7 billion a year earlier, while net income rose to INR 10.3 billion from INR 8.2 billion. Net margin increased from 10.5 percent to 11.3 percent, according to Simply Wall St. The comparison matters because the new products are arriving alongside higher reported profitability, rather than replacing a shrinking revenue base.

Dates investors can track

Simply Wall St lists November 14, 2026 as Aurobindo Pharma's next earnings date. The October 3, 2026 Perampanel announcement remains the latest dated product event in the reviewed reporting.

Market value frames the story

Aurobindo Pharma had a market capitalization of INR 904.3 billion as of October 23, 2026. The stock's 52-week range was INR 1,081.40 to INR 1,740.00 in the same quote snapshot, placing the specialty expansion story against a substantial existing equity value.